This research trial studies quantitative cardiac magnetic resonance imaging in finding heart complications in patients with breast cancer receiving chemotherapy. One of the side effects in patients receiving chemotherapy is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body, which can lead to shortness of breath, swollen ankles and feet, lack of energy, and a reduced capacity to carry out day-to-day activities. Identifying early signs of such heart complications using cardiac magnetic resonance may allow preventative treatment options to be made available in future.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02666378.
PRIMARY OBJECTIVES:
I. To quantify the distributions and temporal changes of cardiac magnetic resonance (CMR) parameters during chemotherapy.
II. To identify CMR predictors of cardiotoxicity in patients receiving anthracycline +/- neoadjuvant therapy.
III. Demonstrate the incremental predictive value of CMR versus (vs.) transthoracic echocardiogram (TTE) and serum biomarkers in cardiotoxicity.
OUTLINE:
Patients undergo CMR at baseline, after completion anthracycline treatment, immediately after completion of all treatments (patients may receive targeted HER2+ positive treatment or other treatments between 3rd and 4th scans), and 12 months after completion of treatment.
After completion of study treatment, patients are followed up in 1 and 2 year intervals.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorReza Nezafat
